Prior to the advances in therapeutics seen over the last decade, the mainstay of treatment for metastatic disease was cytokine-based treatment with high dose interleukin-2 (IL-2) and interferon-alpha (IFN-α) after their FDA approval in the 1990s [10]. Here, IL2 is linked to metastatic neoplasm.